Skip to main navigation

Overview
Corporate
News & Events
Stock Information
Financial Information
- SEC Filings
- Quarterly Results
IR Resources

News & Events

News Releases

News Releases

All
2024
2023
2022
2021
2020
2019

2023.09.07

Adagene to Present at Investor and Scientific Conferences in September

2023.08.31

Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update

2023.05.04

Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate

2023.04.28

Adagene Announces Updates to its Board of Directors

2023.04.18

Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Current page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Displaying 16 - 20 of 79

Shareholder Tools

© 2024 Adagene Inc.

Footer Bottom

Home
Privacy
Terms of Use
Contact
Site Credits
LinkedIn